BIODYNE CO., LTD. Financials Biodyne Co., Ltd.
Equities
A314930
KR7314930009
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,220 KRW | -0.22% |
|
-2.95% | -29.08% |
| 2023 | Biodyne Co., Ltd.(KOSDAQ:A314930) added to S&P Global BMI Index | CI |
| 2023 | Biodyne Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 206,018 | 140,635 | 401,875 |
| Enterprise Value (EV) 1 | 180,579 | 119,912 | 382,161 |
| P/E ratio | -3.64 x | 5.02 x | -390 x |
| Yield | - | - | - |
| Capitalization / Revenue | 54.7 x | 11.5 x | 98.3 x |
| EV / Revenue | 48 x | 9.82 x | 93.5 x |
| EV / EBITDA | -181 x | 14.6 x | -992 x |
| EV / FCF | 158 x | -77.8 x | -2,310 x |
| FCF Yield | 0.63% | -1.28% | -0.04% |
| Price to Book | 5.1 x | 3.04 x | 8.83 x |
| Nbr of stocks (in thousands) | 30,841 | 30,841 | 30,913 |
| Reference price 2 | 6,680 | 4,560 | 13,000 |
| Announcement Date | 22-03-01 | 23-03-01 | 24-02-29 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales 1 | 3,671 | 3,763 | 12,210 | 4,089 |
| EBITDA 1 | -610.7 | -999 | 8,241 | -385.4 |
| EBIT 1 | -1,826 | -2,343 | 6,683 | -2,051 |
| Operating Margin | -49.75% | -62.27% | 54.73% | -50.16% |
| Earnings before Tax (EBT) 1 | -5,060 | -11,138 | 7,366 | -1,221 |
| Net income 1 | -4,454 | -10,857 | 5,611 | -991.8 |
| Net margin | -121.34% | -288.5% | 45.96% | -24.26% |
| EPS 2 | -957.0 | -1,836 | 909.0 | -33.35 |
| Free Cash Flow 1 | -2,719 | 1,141 | -1,541 | -165.4 |
| FCF margin | -74.06% | 30.31% | -12.62% | -4.05% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 21-03-01 | 22-03-01 | 23-03-01 | 24-02-29 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | 5,076 | - | - | - |
| Net Cash position 1 | - | 25,439 | 20,723 | 19,714 |
| Leverage (Debt/EBITDA) | -8.311 x | - | - | - |
| Free Cash Flow 1 | -2,719 | 1,141 | -1,541 | -165 |
| ROE (net income / shareholders' equity) | -57.3% | -47.7% | 13.6% | -2.27% |
| ROA (Net income/ Total Assets) | -4.71% | -4.12% | 9.16% | -2.87% |
| Assets 1 | 94,626 | 263,415 | 61,282 | 34,588 |
| Book Value Per Share 2 | 1,437 | 1,309 | 1,502 | 1,472 |
| Cash Flow per Share 2 | 612.0 | 322.0 | 365.0 | 330.0 |
| Capex 1 | 749 | 836 | 1,435 | 670 |
| Capex / Sales | 20.41% | 22.22% | 11.75% | 16.38% |
| Announcement Date | 21-03-01 | 22-03-01 | 23-03-01 | 24-02-29 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -29.08% | 198M | |
| -3.43% | 12.45B | |
| -3.17% | 8.22B | |
| +31.98% | 5.67B | |
| -10.03% | 4.11B | |
| -59.94% | 2.68B | |
| +11.23% | 2.68B | |
| -5.14% | 2.37B | |
| +18.91% | 2.06B | |
| -7.56% | 1.8B |
- Stock Market
- Equities
- A314930 Stock
- Financials Biodyne Co., Ltd.
